Get the Stockscreener App
11.04
0.09%
-0.01
After Hours:
10.83
-0.21
-1.90%
Mink Therapeutics Inc stock is traded at $11.04, with a volume of 5,992.
It is down -0.09% in the last 24 hours and down -8.00% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$11.05
Open:
$11.2156
24h Volume:
5,992
Relative Volume:
0.38
Market Cap:
$51.82M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-3.638
EPS:
-3.0346
Net Cash Flow:
$-5.58M
1W Performance:
+0.18%
1M Performance:
-8.00%
6M Performance:
-22.25%
1Y Performance:
+17.70%
1-Day Range:
$10.99
$11.27
1-Week Range:
$10.82
$11.48
52-Week Range:
$6.34
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.04 | 51.87M | 0 | -12.36M | -5.58M | -3.0346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Short Covering: Is MiNK Therapeutics Inc a defensive stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 1.6% – Here’s Why - Defense World
Technical Reactions to INKT Trends in Macro Strategies - Stock Traders Daily
MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia - Nasdaq
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - Investing News Network
MiNK Therapeutics Reports Preclinical Data Showing Anti-Fibrotic Effects of Allo-iNKT Cell Therapy for Idiopathic Pulmonary Fibrosis - geneonline.com
MiNK Therapeutics Presents New Data of allo-iNKT Cell - GlobeNewswire
New IPF lung data: key immune cells depleted in advanced disease - Stock Titan
Published on: 2026-02-03 22:53:59 - baoquankhu1.vn
Trading the Move, Not the Narrative: (INKT) Edition - Stock Traders Daily
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to “Hold” - Defense World
Gains Recap: Is Orfa Corp America Preferred Security a stock for growth or value investorsJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold" - MarketBeat
(INKT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Decliners Report: Can MiNK Therapeutics Inc maintain its current growth rate2025 Biggest Moves & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Wall Street Recap: Is MiNK Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
MiNK Therapeutics announces board resignation amid public appointment - MSN
Market Outlook: Why MiNK Therapeutics Inc stock attracts high net worth investorsQuarterly Portfolio Summary & Precise Trade Entry Recommendations - Bộ Nội Vụ
MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Why MiNK Therapeutics Inc. stock remains on watchlists2025 Volume Leaders & Safe Entry Point Alerts - Улправда
How MiNK Therapeutics Inc. (6Q40) stock trades under stagflationWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru
How MiNK Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Free Verified High Yield Trade Plans - Улправда
Why MiNK Therapeutics Inc. stock attracts global investorsShort Setup & Target Return Focused Stock Picks - Улправда
Can MiNK Therapeutics Inc. (6Q40) stock sustain breakout momentum2025 Geopolitical Influence & Reliable Price Action Trade Plans - Улправда
How MiNK Therapeutics Inc. (6Q40) stock behaves under inflation pressureJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
MiNK Therapeutics to begin phase 1 trial of iNKT cell therapy for GvHD - Investing.com Australia
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - The Manila Times
MiNK Therapeutics and University of Wisconsin–Madison - GlobeNewswire
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy to Evaluate Prevention of Graft-Versus-Host Disease - Investing News Network
MiNK Therapeutics announces reverse stock split - MSN
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Will MiNK Therapeutics Inc. stock reach all time highs in 2025Currency Fluctuation Impact & Learn What Analysts Rate “Strong Buy” - Улправда
Price-Driven Insight from (INKT) for Rule-Based Strategy - Stock Traders Daily
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Treasury Yields: How MiNK Therapeutics Inc 6Q40 stock responds to job market shiftsDay Trade & Real-Time Volume Triggers - moha.gov.vn
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Benzinga
Risk Report: Will MiNK Therapeutics Inc 6Q40 stock enhance shareholder valueWeekly Trade Review & Precise Trade Entry Recommendations - moha.gov.vn
The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts - Defense World
MiNK Therapeutics, Inc. Financial Statements – GETTEX:6Q40 - TradingView — Track All Markets
Published on: 2025-12-21 01:45:03 - Улправда
Signal Recap: Why MiNK Therapeutics Inc. (6Q40) stock could rally strongly2025 Geopolitical Influence & Safe Entry Zone Identification - moha.gov.vn
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):